Last update Oct. 12, 2022
Psychostimulant precursor to amphetamine that is metabolized in the body to amphetamine (Cody 2002 and 2001) used as an anti-obesity medication. Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
The paucity of published pharmacokinetic data does not allow prediction of its excretion in human milk, but its metabolite amphetamine is excreted in human milk (Cody 2001), with a T1/2 that would make it necessary to stop breastfeeding for about 100 hours after administration.
It can cause insomnia, anorexia, nervousness, and cardiomyopathy (Montastruc 2010, Cornaert 1986). Due to its negative risk-benefit balance, it has been withdrawn from the market by the main drug agencies (EMA and FDA) of most countries in the world.(Onakpoya 2016, AEMPS 2000)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM